Background. Identifying hepatitis C virus (HCV)-positive persons at high risk of early complications can help prioritize treatment decisions. We conducted this study to compare Child-Turcotte-Pugh (CP), MELD, and FIB-4 scores for predicting clinical outcomes and to identify those at low risk of complications.
The treatment of hepatitis C virus (HCV) infection has been revolutionized with the approvals of several directly acting antiviral agents (DAA). With these new drug combinations, sustained viral eradication can be achieved in over 90% of patients [1] [2] [3] [4] [5] [6] . Although the efficacy of DAAs is firmly established, the cost of a course of therapy is high. Patients, care providers, and payers have struggled to provide treatment to all HCV-infected persons. Some payers have developed criteria to prioritize patients for treatment based on empirical criteria. With cost constraints, and the fact that many HCV-infected persons may have little progression of disease for many years after infection, it is critical to identify those persons with HCV infection who are at highest risk of death or complications. Identification and prioritization of the highest risk patients can help spread the cost of treatment for the larger population over a period of time without jeopardizing the outcomes for those in greatest need of early treatment.
Three widely used criteria to determine the severity of liver injury or presence of fibrosis are the Child-Turcotte-Pugh score (CP), Model for End Stage Liver Disease score (MELD), and the FIB-4 score. Although all provide staging and prognostic information, each was developed for a specific population and for different outcomes. The CP and MELD scores have been used extensively to predict outcomes after surgery in patients with cirrhosis and to assign priority for patients awaiting liver transplantation. However, there is no consensus as to which score is superior in predicting post-surgical outcomes [7] [8] [9] [10] . FIB-4 was developed to predict significant liver fibrosis in HCV/HIV coinfected persons [11] but has subsequently been shown to predict clinical outcomes, including the risk of hepatocellular carcinoma in HCV monoinfected patients [12] [13] [14] . The advantage of using such scores is that they can be derived from readily and routinely available clinical and laboratory information. However, these scores have not been
• CID 2017:65 (1 July) • 65 Predicting clinical outcomes in HCV directly compared with each other for their prognostic value regarding hepatic decompensation, hepatocellular carcinoma, and mortality in HCV infected persons. Our aim was to determine and compare the ability of these 3 noninvasive scores to predict the risk of all-cause mortality, hepatic decompensation and hepatocellular carcinoma at 1, 3, and 5 years after diagnosis of HCV infection.
METHODS

Study Population
We used the Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES) database for this study. Construction of ERCHIVES has been described in numerous previous publications [15] [16] [17] [18] [19] . Briefly, all HCV infected Veterans who received care at any of the Department of Veterans Affairs (VHA) facilities from 2001 onwards are identified based on a positive HCV antibody test. Controls are HCV uninfected persons identified by a negative HCV antibody test in the same year as the HCVpositive case, and matched on age (5-year blocks), race, and sex. Demographic, anthropometric, clinical, laboratory, pharmacy, health factors, and vital signs data are retrieved from VHA's Corporate Data Warehouse (CDW). Data are retrieved using scrambled social security numbers and are merged to yield a comprehensive database of HCV infected persons. The cohort is updated regularly to include newly diagnosed cases.
All HCV antibody-positive persons with detectable HCV RNA within ERCHIVES were eligible for inclusion in this analysis. The baseline was defined as the first positive HCV antibody test date. We excluded those with a diagnosis of HIV coinfection, positive hepatitis B surface antigen, hepatic decompensation, or hepatocellular carcinoma at baseline, missing baseline, or follow-up to calculate the noninvasive scores (FIB-4, MELD, Child-Pugh), missing or undetectable HCV RNA, those who received treatment for HCV for >28 days, and those who died within 3 months of baseline (Figure 1 ). Follow-up began on the initial HCV antibody date and continued until first hepatic decompensation event, hepatocellular carcinoma, death, or last observation date in ERCHIVES. All lab values used to calculate FIB-4, MELD, and CP scores were within 12 months prior to first positive HCV antibody result. For calculation of scores, we used an average of 2 values closest to and before the first HCV-positive date.
Calculation of FIB-4, MELD, and CP Scores:
FIB-4, MELD, and CP scores were calculated based on clinical and laboratory variables recorded closest to, but prior to baseline. FIB-4 was calculated as: To eliminate the possibility of generating negative MELD scores, we set to 1.0 any measured laboratory values that was less than 1.0, so the minimum MELD score a patient could receive was 6.
Child-Turcotte-Pugh score was calculated using a point scoring system for total bilirubin, serum albumin, international normalized ratio (INR), and presence and severity of ascites and hepatic encephalopathy using an algorithm recently published by Kaplan et al [21] . Based on the points accrued, patients were assigned CP class A (5-6 points), B (7-9 points) or C (10-15 points). To account for extreme outliers, we excluded those with values greater than 99.99th percentile for alanine and aspartate aminotransferases. 
Main Study Outcomes
The primary outcomes were incident hepatic decompensation, hepatocellular carcinoma, and all-cause mortality at 1, 3, and 5 years after baseline. Hepatic decompensation was defined using the criteria proposed by Lo Re et al, which has been validated against chart reviews [22] . Hepatocellular carcinoma was identified using ICD-9 codes, a definition that has been used by our team and others [23] . Because hepatic decompensation is among the diagnostic criteria for CP score, we excluded CP score as a predictor of this outcome. Date of death was ascertained from the VA Vital Status file.
As a secondary outcome, we evaluated HCV-related mortality. Cause of death data were identified from the National Death Index maintained by the Centers for Disease Control and Prevention, which lists the primary cause of death. The causes of death were adjudicated by four physician reviewers (2 gastroenterologists/hepatologists and 2 infectious disease specialists) and classified as "definite or possibly HCV-related, " "non-HCV-related, " "liver related, but of unclear etiology, " and "not liver-related. " For the current study, we classified a death as HCV-related if the cause of death was categorized either as definite or possibly HCV-related. Because cause of death data at the time of analysis were available only up until December 2011, we right-censored this analysis at December 31, 2011.
Data Collection
Baseline data included age, sex, race/ethnicity, body mass index, and relevant medical comorbidities, including diabetes mellitus, chronic kidney disease, coronary artery disease, chronic obstructive pulmonary disease, and alcohol and drug abuse and dependence. Diabetes was defined by presence of any of the following criteria: 1) Glucose > 200 mg/dL on 2 separate occasions; 2) ICD-9 codes (2 or more outpatient OR one or more inpatient) PLUS treatment with an oral hypoglycemic or insulin for > 30 days; 3) ICD-9 codes (2 outpatient OR 1 inpatient) PLUS glucose > 126 mg/dL on 2 separate occasions; 4) Glucose > 200 mg/dL on 1 occasion PLUS treatment with an oral hypoglycemic or insulin for > 30 days [24, 25] . Chronic kidney disease was defined by estimating glomerular filtration rate using the CKD-EPI equation [26] . Coronary artery disease [27], chronic obstructive pulmonary disease [28] , and alcohol and drug abuse and dependence [29] were defined by presence of at least 1 inpatient or 2 outpatient ICD-9CM (International Classification of Diseases, 9th edition, Clinical Modification) codes.
Statistical Analyses
We calculated incidence rates per 1,000 patient-years for hepatic decompensation, hepatocellular carcinoma, and overall mortality at 1, 3, and 5 years after the first positive HCV antibody result. We calculated rates of these events according to CP class (A, B, or C, as described above), MELD score categories (<=19; >19), and FIB-4 categories using commonly used cutoff points (<1.45; 1.45-3.25; >3.25). Kaplan-Meier curves were drawn for each of these outcomes, by CP class and MELD and FIB-4 categories. To compare the predictive values of each of these scores for the above mentioned outcomes, we constructed receiver operator curves (ROC) for each outcome and calculated the area under the ROC curve (AUROC) for each scoring system. Child-Pugh score was not used to predict hepatic decompensation due to the reason cited above.
To determine the optimal cut-off values for each score to predict the outcomes of interest (hepatic decompensation, hepatocellular carcinoma, and all-cause mortality at 1, 3, and 5 years), we determined the proportion of persons with those outcomes by CP, MELD, and FIB-4 scores. We also used the ROC curves to determine the cut-off score that minimized the distance on the ROC curve to the "perfect" point (closest to 0,1). We then rounded off the number to the closest whole number to suggest the optimal cut-off for persons in whom the treatment should be prioritized. ROC curves plot the true positive rate against the false positive rate for different cutpoints of a diagnostic test. The area under the ROC curve provides an estimation of the accuracy 
We used SAS® (version 9.4, SAS Institute Inc., Cary, NC, USA) and Stata® version 11 (Stata Corp., College Station, TX, USA) for analyses.
Regulatory Approvals
The study was approved by the Institutional Review Board at VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania. Appropriate approvals were also obtained from each of the databases from which data were retrieved.
RESULTS
The final study cohort consisted of 21 116 chronic HCVinfected persons (Figure 1) (Table 1) .
There were no deaths within the first year of follow up. Higher CP class and FIB-4 score were associated with increased incidence rate of all outcomes (Table 2) . For MELD score, there was a significantly increased incidence of all outcomes with a MELD score of ≥10 compare with a score of <9. However, further categorizing score above 10 did not yield a consistent trend in outcomes.
The cumulative incidences of each outcomes of interest according to CP, MELD, and FIB-4 categories are presented in Supplementary Table 1 . Similar to the findings of the incidence rates, these results show a 3-7-fold higher proportion of deaths in persons with higher CP, MELD, and FIB-4 scores, and a 2-28-fold increase in hepatic decompensation events.
Kaplan-Meier curves demonstrated a significant association between higher CP, MELD, and FIB-4 categories and both overall mortality and mortality at 5 years (P < .001 for all comparisons; Figures 2a and 2b) . Similar curves for hepatic decompensation and hepatocellular carcinoma are provided as supplementary Figures 1 and 2. AUROC for hepatic decompensation at 1, 3, and 5 years were between 0.70-0.86, with consistently higher values (0.84-0.86) for the FIB-4 score compared with the MELD score (0.70-0.76) (P < .001, Figure 4 , upper panel) AUROC for hepatocellular carcinoma at 1, 3, and 5 years were 0.81-0.82 for FIB-4, but 0.61-0.68 for CP and MELD scores. (P < .001, Figure 4 , lower panel) AUROC for mortality at 3 and 5 years were between 0.65 and 0.68, demonstrating poor predictive ability of these measures for mortality. (Figure 3) From the ROC curves, we determined the following optimal cut-off points to identify persons at low risk of complications for various scores: CP score 5; MELD score: 8; FIB-4 score 3 (Supplementary figures 3, 4 , and 5). We tabulated cumulative proportion of persons with events of interest by CP, MELD, and FIB-4 scores (Table 3 and supplementary tables 2, 3, and 4) . At CP score of 5, 3-year mortality was 2.2% and 5-year mortality was 5.7%, and hepatocellular carcinoma was diagnosed in 0.1%, 0.6%, and 1.1% at 1, 3, and 5 years, respectively (Table 3 and  supplementary table 2 ). At MELD score of 8 at 3 and 5 years, mortality was 2.5% and 6.1%, hepatic decompensation at 1, 3, and 5 years was 0.2%, 1.3%, and 2.5% and hepatocellular carcinoma was 0.1%, 0.7%, and 1.3% (Table 3 and supplementary  table 3 ). At FIB-4 score of 3 at 3 and 5 years, mortality was 3.1% and 7.2%, hepatic decompensation at 1, 3, and 5 years was 0.2%, 0.9%, and 1.7% and hepatocellular carcinoma was 0.1%, 0.5%, and 0.8% (Table 3 and supplementary table 4) . Mortality related to definite or possible HCV related liver disease was much higher with increasing disease severity scores (Supplementary table 5 
DISCUSSION
To our knowledge, this is the first study to directly compare 3 commonly used noninvasive markers of liver disease severity for clinical outcomes in HCV-infected persons. We found that increasing CP, MELD, and FIB-4 scores were associated with higher rates of hepatic decompensation, hepatocellular carcinoma, and mortality. We found that FIB-4 score was a superior predictor of hepatic decompensation than MELD score. FIB-4 score was a superior predictor of hepatocellular carcinoma than CP and MELD scores. All 3 scores were poor predictors of mortality.
Our study found that FIB-4 score performed significantly better than MELD score and CP class for predicting incident hepatic decompensation and hepatocellular carcinoma events over 5 years. Although only 0.6% of those with a FIB-4 score <1.45 had a first hepatic decompensation event at 3 years, nearly 15% had an event among those with a FIB-4 score >3. 25 Note: There were no deaths at year 1 and because some hepatic encephalopathy is a part of the CP score, we excluded CP score from the main analysis of these events. Abbreviations: CI, confidence interval; CP, Child-Turcotte-Pugh score; MELD, model for end stage liver disease. patients into more extremes of the severity spectrum, whereas FIB-4 categories are more evenly spread out across the disease spectrum. It is also possible that the measurements that determine these scores represent different types and severity of liver injury. Finally, CP score contains more subjective evaluations, for example, clinical evidence of hepatic encephalopathy, whereas FIB-4 has more objective and concrete measures. How this may affect the predictive ability of each is currently unknown.
Hepatitis C virus infection is a leading cause of hepatocellular carcinoma globally and in the United States [30] . Treatment has been associated with a reduction in the incidence of hepatocellular carcinoma [31] . Published reports suggest that hepatocellular carcinoma develops after decades of HCV infection [30] . In our study, nearly 3% of the persons were diagnosed with hepatocellular carcinoma at 5 years after diagnosis of HCV infection. Among persons with FIB-4 score <1.45, only 0.34% had developed hepatocellular carcinoma at 5 years, whereas among those with FIB-4 score >3.25, over 8% had developed hepatocellular carcinoma. This underscores the need for earlier treatment of HCV to prevent hepatocellular carcinoma, particularly among those with a higher FIB-4 score.
We determined cut-off values for each score below which treatment may reasonably be deferred without jeopardizing clinical outcomes in a large number of patients. At our calculated FIB-4 cut-off of 3, only 0.9% developed hepatic decompensation and 0.5% developed hepatocellular carcinoma at 3 years. However, this must be interpreted with extreme caution. There is no universally accepted norm for acceptable harm when treatment for any condition is deferred for any reason. Such cut-offs are arbitrary, and based on statistical techniques and do not reflect a judgment on morality, ethics, or financial feasibility of treatment. Indeed, when a highly effective treatment is available for a potentially serious disease like HCV, all affected persons should be offered treatment. The VA has recently published guidance to offer treatment to all HCV-infected persons regardless of disease stage [32] . However, current cost of treatment continues to be beyond the reach of most HCV-infected persons globally, and having some objective evidence to prioritize treatment for those most at risk, and conversely defer therapy for those at lower risk of adverse outcomes in the short term may improve overall outcomes in populations. Without such objective evidence, and • CID 2017:65 (1 July) • 71 Predicting clinical outcomes in HCV when resources are insufficient to treat all infected persons, persons at highest risk of complications in the short term may be left untreated.
There are several limitations that need to be taken into account when interpreting our results. As mentioned above, cut-off values are statistical and do not account for social, ethical, moral, and financial factors. The disease severity scores were based on data gathered during routine clinical care and not as part of a rigorous and controlled study. There is a possibility of misclassification using such scores, particularly when some of the components are more subjective, for example, clinical determination of severity of ascites and hepatic encephalopathy. However, we and others have validated these scores in various settings and found them to correlate with existing gold standards. The study was limited to veterans in care with the VA healthcare system, and its generalizability to the larger population is unknown.
In summary, we found that FIB-4 was superior to the CP and MELD scores for prediction of incident hepatic decompensation and hepatocellular carcinoma events among chronic HCVinfected persons. At a FIB-4 cut-off score of 3, less than 1% of chronic HCV-infected patients developed hepatic decompensation or hepatocellular carcinoma. These results may help guide providers in prioritizing HCV-infected patients for treatment when resources to treat all HCV infected persons are not available.
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